Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin.
Current treatment strategies for high-grade gliomas are inadequate with high rates of disease recurrence and poor overall survival. Photodynamic therapy has been extensively investigated for a variety of tumours including high-grade gliomas. We have previously described a novel boronated porphyrin (BOPP) which has highly selective uptake by tumour cells. A Phase I study documented that BOPP at a dose of 4mg/kg was well tolerated. We report here the survival data arising from this Phase I study. Overall 28 patients (pts) with high-grade gliomas were treated with BOPP photodynamic therapy with a median overall survival (OS) of 14 months (2-48+ months). Sixteen pts had glioblastoma multiforme (GBM) with a median OS of 8 months (2-38+). Of 9 pts with recurrent GBM, the median OS was 11 months (3-38+), with 56% surviving at least 12 months. In conclusion, BOPP photodynamic therapy was associated with encouraging survival particularly in the recurrent GBM setting.
Rosenthal
Mark A
MA
Centre for Developmental Cancer Therapeutics, Parkville, Victoria, Australia. mark.rosenthal@mh.org.au
Kavar
Bhadu
B
Uren
Shannon
S
Kaye
Andrew H
AH
D000328:Adult; D000368:Aged; D001896:Boron Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016754:Boron Neutron Capture Therapy; D003905:Deuteroporphyrins / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005910:Glioma / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D017741:Survivors; D000098851:Carboranes
D001896:Boron Compounds; D003905:Deuteroporphyrins; C080251:2,4-(alpha,beta-dihydroxyethyl)deuteroporphyrin IX tetrakiscarborane carboxylate ester; D000098851:Carboranes